Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands.
Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands.
Sci Adv. 2022 Dec 14;8(50):eadc9937. doi: 10.1126/sciadv.adc9937.
Universal influenza vaccines should protect against continuously evolving and newly emerging influenza viruses. T cells may be an essential target of such vaccines, as they can clear infected cells through recognition of conserved influenza virus epitopes. We evaluated a novel T cell-inducing nucleoside-modified messenger RNA (mRNA) vaccine that encodes the conserved nucleoprotein, matrix protein 1, and polymerase basic protein 1 of an H1N1 influenza virus. To mimic the human situation, we applied the mRNA vaccine as a prime-boost regimen in naïve ferrets (mimicking young children) and as a booster in influenza-experienced ferrets (mimicking adults). The vaccine induced and boosted broadly reactive T cells in the circulation, bone marrow, and respiratory tract. Booster vaccination enhanced protection against heterosubtypic infection with a potential pandemic H7N9 influenza virus in influenza-experienced ferrets. Our findings show that mRNA vaccines encoding internal influenza virus proteins represent a promising strategy to induce broadly protective T cell immunity against influenza viruses.
通用流感疫苗应该能够预防不断进化和新出现的流感病毒。T 细胞可能是此类疫苗的一个重要靶点,因为它们可以通过识别保守的流感病毒表位来清除受感染的细胞。我们评估了一种新型的 T 细胞诱导的核苷修饰信使 RNA(mRNA)疫苗,该疫苗编码 H1N1 流感病毒的保守核蛋白、基质蛋白 1 和聚合酶碱性蛋白 1。为了模拟人类情况,我们将 mRNA 疫苗作为基础-加强方案应用于天真的雪貂(模拟儿童),并作为加强剂应用于有流感经验的雪貂(模拟成人)。该疫苗在循环、骨髓和呼吸道中诱导和增强了广泛反应性的 T 细胞。加强疫苗接种增强了对有潜在大流行风险的 H7N9 流感病毒的异亚型感染的保护作用,在有流感经验的雪貂中。我们的研究结果表明,编码流感病毒内部蛋白的 mRNA 疫苗是诱导针对流感病毒的广泛保护性 T 细胞免疫的一种有前途的策略。